tetano
Editor, Senior Moderator
Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180. [h=1]Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.[/h]
Bersanelli M[SUP]1,[/SUP][SUP]2[/SUP], Buti S[SUP]1[/SUP], Banna GL[SUP]3[/SUP], Giorgi U[SUP]4[/SUP], Cortellini A[SUP]5,[/SUP][SUP]6[/SUP], Rebuzzi SE[SUP]1,[/SUP][SUP]7[/SUP], Tiseo M[SUP]1,[/SUP][SUP]2[/SUP], Fornarini G[SUP]7[/SUP], Mazzoni F[SUP]8[/SUP], Panni S[SUP]9[/SUP], Tursi M[SUP]10[/SUP], Marino PD[SUP]10[/SUP], Rossetti S[SUP]11[/SUP], Rossi E[SUP]12[/SUP], Tomao S[SUP]13[/SUP], Luca E[SUP]14[/SUP], Sorar? M[SUP]15[/SUP], Mucciarini C[SUP]16[/SUP], Atzori F[SUP]17[/SUP], Torre L[SUP]18[/SUP], Vitale MG[SUP]19[/SUP], Martelli V[SUP]7[/SUP], Sepe P[SUP]20[/SUP], Mollica V[SUP]21[/SUP], Vaccaro V[SUP]22[/SUP], Schinzari G[SUP]12[/SUP], Ficorella C[SUP]6,[/SUP][SUP]7[/SUP], Massari F[SUP]21[/SUP], Maestri A[SUP]18[/SUP], Sabbatini R[SUP]19[/SUP], Sava T[SUP]15[/SUP], Maio MD[SUP]14[/SUP], Verzoni E[SUP]20[/SUP], Procopio G[SUP]20[/SUP], Giannarelli D[SUP]23[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
[h=4]KEYWORDS:[/h] flu vaccine; immune checkpoint inhibitors; immunotherapy; influenza syndrome; influenza vaccination; overall survival
PMID: 32089035 DOI: 10.2217/imt-2019-0180
Bersanelli M[SUP]1,[/SUP][SUP]2[/SUP], Buti S[SUP]1[/SUP], Banna GL[SUP]3[/SUP], Giorgi U[SUP]4[/SUP], Cortellini A[SUP]5,[/SUP][SUP]6[/SUP], Rebuzzi SE[SUP]1,[/SUP][SUP]7[/SUP], Tiseo M[SUP]1,[/SUP][SUP]2[/SUP], Fornarini G[SUP]7[/SUP], Mazzoni F[SUP]8[/SUP], Panni S[SUP]9[/SUP], Tursi M[SUP]10[/SUP], Marino PD[SUP]10[/SUP], Rossetti S[SUP]11[/SUP], Rossi E[SUP]12[/SUP], Tomao S[SUP]13[/SUP], Luca E[SUP]14[/SUP], Sorar? M[SUP]15[/SUP], Mucciarini C[SUP]16[/SUP], Atzori F[SUP]17[/SUP], Torre L[SUP]18[/SUP], Vitale MG[SUP]19[/SUP], Martelli V[SUP]7[/SUP], Sepe P[SUP]20[/SUP], Mollica V[SUP]21[/SUP], Vaccaro V[SUP]22[/SUP], Schinzari G[SUP]12[/SUP], Ficorella C[SUP]6,[/SUP][SUP]7[/SUP], Massari F[SUP]21[/SUP], Maestri A[SUP]18[/SUP], Sabbatini R[SUP]19[/SUP], Sava T[SUP]15[/SUP], Maio MD[SUP]14[/SUP], Verzoni E[SUP]20[/SUP], Procopio G[SUP]20[/SUP], Giannarelli D[SUP]23[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
[h=4]KEYWORDS:[/h] flu vaccine; immune checkpoint inhibitors; immunotherapy; influenza syndrome; influenza vaccination; overall survival
PMID: 32089035 DOI: 10.2217/imt-2019-0180